undamentalytics Newsletter
Sign in

Vanda Pharmaceuticals Inc. balance sheet

At the end of fiscal 2025, Vanda Pharmaceuticals Inc. had total assets of $489m, total liabilities of $162m and shareholders' equity of $327m. It held $84.9m in cash against $0 of debt: net cash of $84.9m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash and equivalents2054388896561514034614561521351361028562
Receivables—12124162018292630323434475560
Inventory———0—5111111111222
Total current assets—201154126136142167174170299354409478519433439347238
Total assets—213183135143172213210205332484533594634648656489382
Accounts payable—11011————————————
Deferred revenue (current)—272727270————————————
Total current liabilities—313232338515070536066749188100145155
Total debt000000000000000000
Total liabilities—175149126991180797457738089107104118162182
Shareholders' equity2338331044161133131131275411453505527545539327200
Net debt (negative = net cash)−205−43−88−89−65−61−51−40−34−61−45−61−52−135−136−102−85−62
Shares outstanding—28m28m28m33m41m43m44m45m52m54m55m56m57m58m58m59m60m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ACB vs VNDAHROW vs VNDAOGI vs VNDA

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Vanda Pharmaceuticals Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Vanda Pharmaceuticals Inc.